Clinical trials: sponsored by Canadian Cancer Trials Group
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
This phase III trial investigates how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer.
- Conditions
- Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8
- Trial name
- NCT03233711
- Testing
- Biopsy Procedure, Biospecimen Collection, Colonoscopy
- Where
- 896 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- National Cancer Institute (NCI)
NSCLC
Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer
This study is being done to answer the following question: What are the effects of new treatments on non-small cell lung cancer before surgery?
- Trial name
- NCT05714891
- Testing
- JDQ443
- Where
- 8 sites in Canada
- Volunteers
- 4 people
- Sponsor
- Canadian Cancer Trials Group
Non Small Cell Lung Cancer
Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer
This study is being done to answer the following question: Can adding a treatment called Fecal Microbiota Transplant (FMT) to the usual treatment delay the growth or spread of cancer better than the usual treatment alone? FMT…
- Trial name
- LUNA-2 (NCT07890493)
- Testing
- LND101, Carboplatin (AUC 5 or 6), pemetrexed
- Volunteers
- 160 people
- Sponsor
- Canadian Cancer Trials Group
Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has…
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
- Trial name
- NCT03914612
- Testing
- Carboplatin, Computed Tomography, Paclitaxel
- Where
- 397 sites in United States, Canada and 3 more
- Volunteers
- 813 people
- Sponsor
- National Cancer Institute (NCI)
Breast Screening
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer.
- Trial name
- NCT03233191
- Testing
- Digital Mammography, Digital Tomosynthesis Mammography, Laboratory Biomarker Analysis
- Where
- 149 sites in United States, Argentina and 9 more
- Volunteers
- 108,508 people, healthy volunteers welcome
- Sponsor
- ECOG-ACRIN Cancer Research Group
Cancer Metastatic
Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases
This study is being done to answer the following question: Is Stereotactic Body Radiation Therapy or SBRT (a form of radiation therapy which can deliver high doses of radiation to the specific painful area of the body most…
- Trial name
- NCT06391242
- Testing
- Standard Conventional Radiotherapy, Stereotactic Body Radiotherapy
- Where
- 12 sites in Canada
- Volunteers
- 230 people
- Sponsor
- Canadian Cancer Trials Group
Alveolar Soft Part Sarcoma, Renal Cell Carcinoma
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Only enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what…
- Conditions
- Alveolar Soft Part Sarcoma, Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT07297667
- Testing
- Fludarabine, Cyclophosphamide, GCAR1
- Where
- 4 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Canadian Cancer Trials Group
Multiple Myeloma
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Currently, daratumumab or isatuximab are given continuously (non-stop), along side lenalidomide, and dexamethasone as part of multiple myeloma treatment. are given continuously (non-stop).
- Trial name
- NCT06182774
- Testing
- Daratumumab, Lenalidomide, Dexamethasone
- Where
- 31 sites in Canada
- Volunteers
- 570 people
- Sponsor
- Canadian Cancer Trials Group
Endometrial Cancer
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC).
- Trial name
- NCT05640999
- Testing
- Vaginal brachytherapy, Adjuvant radiotherapy (EBRT +/- brachytherapy), Observation
- Where
- 123 sites in United States, Australia and 7 more
- Volunteers
- 393 people
- Sponsor
- Canadian Cancer Trials Group
Advanced Head and Neck Cancer
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer
This study is being done to answer the following question: Does stereotactic body radiation therapy (SBRT) provide better cancer control compared to standard radiation therapy (RT) for those with advanced head and neck cancer?
- Trial name
- NCT06641791
- Testing
- Standard Radiotherapy (SRT), Stereotactic Body Radiotherapy (SBRT)
- Where
- 10 sites in Canada
- Volunteers
- 196 people
- Sponsor
- Canadian Cancer Trials Group
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:
Utilization data will be collected from all patients entered on the trial at Canadian centres from the time of registration until death, removal from study, or completion of 10 years of follow-up.
- Trial name
- NCT05371808
- Testing
- EQ-5D-5L Instrument, Work Productivity and Daily Activity Impairment (WPAI) survey, Resource Utilization Form (SMRC)
- Where
- 6 sites in Canada
- Volunteers
- 247 people
- Sponsor
- Canadian Cancer Trials Group
Cancer
Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials
This study is being done to answer the following question: Are patients on a clinical trial willing to provide answers to questions about their social, economic, and environmental factors-sometimes called social determinants of…
- Trial name
- FACTOR (NCT07390435)
- Testing
- Social Determinants of Health Questionnaire
- Where
- 15 sites in Canada
- Volunteers
- 1,000 people
- Sponsor
- Canadian Cancer Trials Group
Mantle Cell Lymphoma
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
The purpose of this study is to evaluate the effects of adding two oral medications (sonrotoclax plus zanubrutinib) to standard of care chimeric antigen receptor (CAR-T) cell therapy in participants with mantle cell lymphoma.
- Trial name
- NCT07341191
- Testing
- Zanubrutinib, Sonrotoclax, CAR-T Cell Therapy
- Where
- 5 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Canadian Cancer Trials Group
Endometrial Cancer
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
RAINBO MMRd-GREEN is an international, multicenter, phase III randomised trial wherein adjuvant pelvic external beam radiotherapy combined with and followed by durvalumab for one year is compared to adjuvant pelvic external beam…
- Trial name
- RAINBO-GREEN (NCT05255653)
- Testing
- Pelvic external beam radiotherapy, Chemotherapy, Durvalumab
- Where
- 60 sites in Belgium, Canada and 5 more
- Volunteers
- 316 people
- Sponsor
- Leiden University Medical Center
IDH-mutant Grade 2 or 3 Astrocytoma
Vorasidenib Maintenance for IDH Mutant Astrocytoma
The main goal of VIGOR is to demonstrate that vorasidenib maintenance therapy improves locally assessed progression-free survival (PFS) from enrolment compared to placebo in patients with IDH-mutant, CNS5 WHO Grade 2 or 3…
- Trial name
- VIGOR (NCT06809322)
- Testing
- Vorasidenib
- Where
- 59 sites in Australia, Austria and 10 more
- Volunteers
- 468 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Retroperitoneal Sarcoma, Liposarcoma
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS…
- Conditions
- Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
- Trial name
- STRASS2 (NCT04031677)
- Testing
- Surgery, Preoperative chemotherapy
- Where
- 176 sites in United States, Australia and 13 more
- Volunteers
- 250 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
- Trial name
- NCT02502266
- Testing
- Cediranib, Cediranib Maleate, Computed Tomography
- Where
- 398 sites in United States, Canada and 3 more
- Volunteers
- 582 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl…
- Trial name
- NCT02003222
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab
- Where
- 544 sites in United States, Canada and 2 more
- Volunteers
- 488 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
The purpose of this study is to find out what effects new combinations of treatment will have this disease. New promising treatment strategies will be added to this study as they are available to be compared against the standard…
- Trial name
- NCT02436707
- Testing
- Ibrutinib, Rituximab, Gemcitabine
- Where
- 11 sites in Canada
- Volunteers
- 129 people
- Sponsor
- Canadian Cancer Trials Group
Ovarian Cancer Prevention
ASA in Prevention of Ovarian Cancer (STICs and STONEs)
While ASA is not a cancer medication, research suggests that taking ASA reduces the probability of getting many types of cancer because of its anti-inflammatory action.
- Trial name
- NCT03480776
- Testing
- Acetylsalicylic acid
- Where
- 17 sites in Australia, Canada
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Canadian Cancer Trials Group